3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Interventions
venetoclax
1
prednylidene
1
navitoclax
1
deltacortene
1
Vincristine
1
Rituximab
1
Prednisone
1
Leyk
1
Imatinib Mesylate
1
Etoposide
1
Doxorubicin
1
Decitabine
1
Cyclophosphamide
1
Asparaginase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
×
navitoclax
×
Clear all
NCT05740449
2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2
Withdrawn